Benefit-Risk Assessment Flashcards

In a benefit-risk assessment, the 'comparator' is most appropriately chosen as:

Answer: The current standard of care or best available therapy for the same indication

The comparator should represent what patients would realistically receive otherwise, typically the current standard of care, to make the benefit-risk comparison clinically meaningful.

Which concept describes the minimum clinically meaningful improvement that a drug must demonstrate to justify its risks?

Answer: Minimal clinically important difference (MCID)

The MCID defines the smallest change in a clinical outcome that patients and clinicians consider meaningful, setting the threshold for clinical relevance in benefit-risk assessment.

Under FDA regulations, for which category of drug would a formal REMS most likely be required based on benefit-risk considerations?

Answer: A drug with serious known risks that can only be managed through restricted distribution

FDA requires REMS when a drug has serious risks that necessitate restrictions beyond standard labeling to ensure benefits outweigh risks in the real world.

A stochastic simulation in benefit-risk assessment is used primarily to:

Answer: Model uncertainty around benefit and risk estimates using probability distributions

Stochastic simulations use Monte Carlo methods to propagate uncertainty in input parameters, providing probability distributions around benefit-risk estimates.

Which of the following BEST exemplifies a situation where the benefit-risk balance of an approved drug would be considered 'context-dependent'?

Answer: A drug that is favorable for patients with severe refractory disease but unfavorable for patients with mild disease

Context-dependence means the balance shifts based on disease severity, patient characteristics, or treatment alternatives, requiring tailored benefit-risk labeling or restrictions.

In the 'consequence' step of the PrOACT-URL framework, the assessor is expected to:

Answer: Describe the outcomes of each alternative for each criterion

The Consequences step describes the likely outcomes (benefits and risks) of each alternative option, providing the evidence base for subsequent trade-off analysis.

Which regulatory concept allows a drug with unresolved safety uncertainties to be conditionally approved, with benefit-risk reassessment tied to post-marketing data?

Answer: Conditional Marketing Authorization

Conditional Marketing Authorization (EMA) or similar pathways allow approval when benefits outweigh risks, contingent on the sponsor fulfilling specific post-marketing obligations to resolve uncertainties.